Nventa appoints Sandford D. Smith to Board of Directors

    - New Member Brings Significant Global Experience in Bio/Pharmaceutical
    Development and Commercialization -

    SAN DIEGO, CA, June 12 /CNW/ - Nventa Biopharmaceuticals Corporation
(TSX:NVN) announced today the appointment of Sandford D. Smith to its Board of
Directors. Mr. Smith is currently President of the International Group and
Executive Vice President at Genzyme Corporation. Mr. Smith replaces Ms.
Elizabeth Greetham.
    Jay M. Short, Ph.D., Chairman of the Board of Directors at Nventa,
commented on the appointment: "We are very pleased to welcome Sandy Smith to
Nventa's Board. His extensive global experience in the biotechnology field
should prove invaluable to us as we grow and continue to guide Nventa through
its strategic decisions. I would also like to thank Elizabeth Greetham for her
hard work and efforts on the Nventa Board. Over the last five years,
Elizabeth's knowledge of the financial and investment communities and the
biotechnology field has been a tremendous asset. We will miss her and wish her
continued success in all of her future endeavors."
    "Sandy has played an integral role in the development of Genzyme as a
global organization, one of the most successful biotechnology companies
today," said Gregory M. McKee, President and Chief Executive Officer at
Nventa. "His wealth of knowledge and experience in developing and
commercializing biologics and therapeutics complements the existing talent on
the Nventa Board."
    Having joined Genzyme in 1996, Mr. Smith is responsible for all of
Genzyme's commercial activities outside of the United States. Mr. Smith served
as Vice President and General Manager of Genzyme International and President
of Genzyme Specialty Therapeutics before being named to his current position
in 2006. Prior to joining Genzyme, Mr. Smith was President and Chief Executive
Officer at Repligen Corporation. He has served as Vice President of Business
Development and Strategic Planning for Bristol-Myers Squibb Company. Mr. Smith
has a B.A. from the University of Denver.
    Mr. Smith serves as Vice Chairman on the Board of Ariad Pharmaceuticals,
Inc. and is on the Board of Directors and Executive Committee of the Boston
Philharmonic Orchestra.

    About Nventa Biopharmaceuticals Corporation:
    Nventa is developing innovative therapeutics for the treatment of viral
infections and cancer, with a focus on diseases caused by the human
papillomavirus (HPV). The Company is publicly traded on the Toronto Stock
Exchange under the symbol NVN. For more information about Nventa
Biopharmaceuticals Corporation, please visit the Company's website located at

    %SEDAR: 00023483E

For further information:

For further information: Donna Slade, Director, Investor Relations, 9381
Judicial Drive, Suite 180, San Diego, CA, USA, 92121, Dir: (858) 202-4945,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890